EP Patent

EP4727526A1 — Topical skin formulations of a pharmaceutically acceptable salt of ruxolitinib

Assigned to Incyte Corp · Expires 2026-04-22 · 0y expired

What this patent protects

This invention relates to topical skin formulations comprising a pharmaceutically acceptable salt of ruxolitinib, and use in the treatment of skin disorders.

USPTO Abstract

This invention relates to topical skin formulations comprising a pharmaceutically acceptable salt of ruxolitinib, and use in the treatment of skin disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4727526A1
Jurisdiction
EP
Classification
—
Expires
2026-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.